Abstract
Background: Comparative studies in paediatric-onset multiple sclerosis (PoMS) that also include highly effective monoclonal antibody therapies are rare. Objective: To compare treatment persistence, as a proxy of effectiveness and tolerability, across disease-modifying therapies (DMTs). Methods: Nationwide cohort study using Swedish MS Registry data on individuals with MS onset before age 18 from 2000 to 2024. Treatment persistence was analysed using Kaplan–Meier and Cox models, adjusted for demographics and treatment epoch. Results: We included 383 individuals (69.2% female; median onset age 15.8 and 17.2 years at first DMT start), observed for a median 10.1 years (interquartile range (IQR): 5.5–15.5), yielding 934 treatment episodes: rituximab (272), injectables (263), natalizumab (248), fingolimod (86) and dimethyl fumarate (65). Median age at any treatment initiation, regardless of treatment sequence, was 18.9 years, with a median Expanded Disability Status Scale (EDSS) score of 1.5 (IQR: 0.0–2.0). Treatment persistence never dropped below 50% for rituximab, while median persistence was 35.6 months for natalizumab (95% confidence interval (CI): 28.8–44.9), 34.7 for dimethyl fumarate (95% CI: 21.7–56.9), 32.0 for fingolimod (95% CI: 21.1–48.1) and 17.6 for injectables (95% CI: 14.4–20.8). Compared to injectables, adjusted hazard ratios (HRs) for discontinuation were significantly lower for rituximab (0.09; 95% CI: 0.07–0.12), natalizumab (0.39; 95% CI: 0.31–0.48), fingolimod (0.41; 95% CI: 0.30–0.55) and dimethyl fumarate (0.49; 95% CI: 0.36–0.68). Conclusion: Rituximab displayed the highest treatment persistence, supporting B-cell depletion as a first-line option in PoMS.
Funding Information
  • The Swedish Brain Fund
  • Sällskapet Barnavård
  • Erling-Perssons Stiftelse
  • Svenska Forskningsrådet Formas
  • Bjarne Ahlström’s Memorial Fund
  • Region Stockholm
  • Kronprinsessan Lovisas förening för barnasjukvård och Stiftelsen Axel Tielmans Minnesfond
  • Stiftelsen Samariten

This publication has 30 references indexed in Scilit: